Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016237 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
A Phase 1 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00016237 is a Phase 1 study that has completed, run by EMD Serono.
The verdict
NCT00016237, a Phase 1 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 combined with a monoclonal antibody may be an effective treatment for kidney, bladder, or lung cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 combined with a monoclonal antibody in treating patients who have kidney, bladder, or lung cancer that has not responded to previous treatment.
Interventions
- BIOLOGICAL tucotuzumab celmoleukin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016237
The ClinicalTrials.gov registry entry for NCT00016237 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tucotuzumab celmoleukin is the first listed.
NCT00016237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016237 about?
NCT00016237 is a clinical study titled "Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 combined with a monoclonal antibody may be an effective t...
What is the current status of trial NCT00016237?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-12.
What interventions are being tested in trial NCT00016237?
The interventions under investigation include: tucotuzumab celmoleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00016237?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.